A detailed history of Rothschild Investment Corp transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Rothschild Investment Corp holds 40,084 shares of PCRX stock, worth $696,659. This represents 0.1% of its overall portfolio holdings.

Number of Shares
40,084
Previous 40,327 0.6%
Holding current value
$696,659
Previous $1.62 Million 23.84%
% of portfolio
0.1%
Previous 0.13%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 16, 2023

SELL
$30.68 - $40.09 $7,455 - $9,741
-243 Reduced 0.6%
40,084 $1.23 Million
Q2 2023

Jul 18, 2023

BUY
$36.12 - $47.5 $1.12 Million - $1.47 Million
31,033 Added 333.9%
40,327 $1.62 Million
Q4 2022

Jan 19, 2023

BUY
$38.19 - $57.45 $2,405 - $3,619
63 Added 0.68%
9,294 $359,000
Q2 2022

Jul 12, 2022

BUY
$51.49 - $81.64 $8,959 - $14,205
174 Added 1.92%
9,231 $539,000
Q1 2022

Apr 18, 2022

BUY
$60.03 - $76.49 $8,044 - $10,249
134 Added 1.5%
9,057 $692,000
Q3 2021

Oct 12, 2021

SELL
$54.64 - $61.3 $546 - $613
-10 Reduced 0.11%
8,923 $500,000
Q2 2021

Jul 19, 2021

SELL
$59.18 - $69.99 $14,676 - $17,357
-248 Reduced 2.7%
8,933 $542,000
Q1 2021

Apr 15, 2021

BUY
$59.31 - $78.82 $58,776 - $78,110
991 Added 12.1%
9,181 $643,000
Q4 2020

Jan 25, 2021

SELL
$50.47 - $66.26 $40,779 - $53,538
-808 Reduced 8.98%
8,190 $490,000
Q3 2020

Oct 22, 2020

BUY
$51.97 - $63.0 $48,799 - $59,157
939 Added 11.65%
8,998 $541,000
Q2 2020

Jul 24, 2020

SELL
$30.8 - $52.47 $546,823 - $931,552
-17,754 Reduced 68.78%
8,059 $423,000
Q1 2020

Apr 16, 2020

BUY
$28.4 - $50.7 $545,393 - $973,642
19,204 Added 290.57%
25,813 $866,000
Q4 2019

Jan 22, 2020

BUY
$36.31 - $46.83 $239,972 - $309,499
6,609 New
6,609 $299,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $796M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Rothschild Investment Corp Portfolio

Follow Rothschild Investment Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild Investment Corp , based on Form 13F filings with the SEC.

News

Stay updated on Rothschild Investment Corp with notifications on news.